Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dextracal is an oral nutritional supplement developed and marketed by Astrum Healthcare. It is formulated as both tablets and a suspension, containing a combination of calcium carbonate and cholecalciferol (Vitamin D3). The product is primarily indicated for the prevention and treatment of calcium and Vitamin D deficiencies, which are essential for maintaining bone mineral density and preventing conditions such as osteoporosis, osteomalacia, and rickets. Calcium carbonate serves as a source of elemental calcium, a primary structural component of the bone matrix. Cholecalciferol acts as a Vitamin D receptor agonist, facilitating the intestinal absorption of calcium and maintaining systemic calcium homeostasis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on calcium carbonate + cholecalciferol (Astrum Healthcare).